A candidate treatment for patients with glaucoma, Vesneo, has reached its primary endpoint in a Phase 3 development programme, showing that it can effectively lower intraocular pressure, according to Nicox SA, the developer. ---Subscribe to MedNous to access this article--- Clinical Research Company News
